Trials / Unknown
UnknownNCT02282436
Substudy : Patients With an Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Muscle Atrophy in Patients With Chronic Obstructive Pulmonary DIsease : Substudy With Patients Who Experienced an Acute Exacerbation
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 20 (estimated)
- Sponsor
- Laval University · Academic / Other
- Sex
- All
- Age
- 50 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide. Its prevalence is in progression and COPD is expected to become the fourth leading cause of death by 2030. COPD is characterized by periods of stability interspersed with acute infectious/inflammatory flare-ups, also called acute exacerbations, during which patients deteriorate, sometimes to the point of requiring immediate medical assistance. Although most patients eventually recover, repeated episodes of exacerbations may accelerate COPD progression. Exacerbations may further compromise the integrity of limb muscles by promoting further loss in muscle mass and strength. The overall objective of this substudy is to elucidate how an acute COPD exacerbation may affect limb muscles.
Detailed description
Focusing our attention during exacerbations, a period of aggravated systemic inflammation, should be more rewarding in terms of understanding the link between inflammation burst and muscle disease in COPD. We have recently acquired experimental data supporting a role for the ubiquitin proteasome pathway in the worsening of limb muscle structure and function during an acute exacerbation, providing a solid framework for this investigation. The overall objective of this proposal is to substantiate these preliminary findings and elucidate how systemic inflammation during acute COPD exacerbation may affect limb muscles. Ultimately, our research could open new therapeutic avenues to minimize the systemic consequences of an acute exacerbation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | No specific intervention for this study | No specific intervention for this study |
Timeline
- Start date
- 2012-05-01
- Primary completion
- 2017-05-01
- Completion
- 2018-05-01
- First posted
- 2014-11-04
- Last updated
- 2016-09-08
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT02282436. Inclusion in this directory is not an endorsement.